iShares Biotechnology ETF
IBB
797 hedge funds and large institutions have $3.94B invested in iShares Biotechnology ETF in 2025 Q2 according to their latest regulatory filings, with 57 funds opening new positions, 136 increasing their positions, 350 reducing their positions, and 82 closing their positions.
28% more call options, than puts
Call options by funds: $216M | Put options by funds: $168M
5.25% more ownership
Funds ownership: 68.77% → 74.02% (+5.2%)
1% less capital invested
Capital invested by funds: $3.98B → $3.94B (-$38.4M)
4% less funds holding
Funds holding: 831 → 797 (-34)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
30% less first-time investments, than exits
New positions opened: 57 | Existing positions closed: 82
61% less repeat investments, than reductions
Existing positions increased: 136 | Existing positions reduced: 350
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$240M |
| 2 |
Citigroup
New York
|
+$106M |
| 3 |
Morgan Stanley
New York
|
+$100M |
| 4 |
JP Morgan Chase
New York
|
+$43.6M |
| 5 |
ERSOT
Employees Retirement System of Texas
Austin,
Texas
|
+$24.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$102M |
| 2 |
MMEA
Main Management ETF Advisors
San Francisco,
California
|
-$78.3M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
-$55.5M |
| 4 |
Barclays
London,
United Kingdom
|
-$40.6M |
| 5 |
Two Sigma Investments
New York
|
-$35.5M |
IBB Hedge Fund Activity: Q2 2025 in Review
797 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q2 2025, worth a combined $3.94B — down 0.96% from $3.98B a quarter earlier.
Sellers outnumbered buyers: 82 funds closed out of IBB and 57 opened new positions — a net loss of 25 holders — while 350 trimmed existing stakes and 136 added.
The largest buyer was Goldman Sachs, adding an estimated $240M. The largest seller was Bank of America, cutting an estimated $102M.
- 797 institutional investors held iShares Biotechnology ETF (IBB) as of Q2 2025, down from 831 in Q1 2025.
- Funds reported $3.94B of iShares Biotechnology ETF stock for Q2 2025, down 0.96% quarter-over-quarter.
- 57 funds opened new iShares Biotechnology ETF positions in Q2 2025 and 82 closed out, a net change of -25 holders.
- The largest iShares Biotechnology ETF buyer in Q2 2025 was Goldman Sachs, an estimated $240M added.
- The largest iShares Biotechnology ETF seller in Q2 2025 was Bank of America, an estimated $102M sold.
Based on aggregated 13F filings for Q2 2025.